SRXN1 Antibody

1. NRF2, DJ1 and SRNX1 are commonly expressed in diffusely infiltrating astrocytomas and they can be used in predicting patient prognosis. PMID: 29441509
2. Study identify a role for Srxn1 as a denitrosylase for neuronal Prx2. Finding points to the NO/Srxn1 pair in a previously unrecognized redox cycle that modulates Prx2 peroxidase activity. PMID: 27821734
3. Wnt/beta-catenin pathway was stimulated by sulfiredoxin in tumor cell line, with activation of CD44-its target genes-resulting in the promotion of invasion and migration in cervical cancer cell lines. PMID: 28448437
4. This review will highlight the cumulative effects of sulfiredoxin in various systemic disorders with a strong emphasis on its target activity and the factors influencing its expression in such conditions. PMID: 25460739
5. The up-regulated expression of Srx was significantly associated with lymph node metastasis, infiltration of vessels, and the depth of cancer invasion. PMID: 28274319
6. The analysis of SXR polymorphism is a promising tool to predict both the favourable response to corticosteroids and the risk of developing steroid resistance PMID: 27377607
7. rs6053666 of SRXN1 is associated with cerebrovascular disease in a Finnish cohort PMID: 27226772
8. Increased expression of Srx protects peroxiredoxins against hyperoxidation in the early stage of hyperglycaemia. PMID: 28202395
9. We silenced Srx by short hairpin RNA in HeLa and SiHa cells. Diminished Srx expression upregulated E-cadherin expression. The cell invasion and migration activity in the ShSrx group were obviously decreased in HeLa and SiHa cells. PMID: 28351308
10. Study shows that Srx plays a critical oncogenic role to promote cell invasion and metastasis, which is at least partially due to its stimulation of the MAPK pathway through EGFR deacetylation. PMID: 26290602
11. This review will summarize the molecular basis of differences in the affinity of Srx for individual Prx and the role of individual component of the Srx-Prx system in tumor progression and metastasis. PMID: 26170166
12. Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-beta. PMID: 22879602
13. NRF2 and SRXN1 genetic polymorphisms are associated with breast cancer risk and survival PMID: 22964583
14. SRX forms a complex with S100A4 (and has stronger affinity for S-glutathionylated S100A4), regulates its activity, and mediates redox regulation of the interaction of S100A4 with nonmuscle myosin heavy chain II-A. PMID: 22934964
15. Smokers and ex-smokers had significantly more sulfiredoxin expression in their tumors and in patients receiving cytostatic drugs or radiation therapy, sulfiredoxin expression predicted a poor prognosis. PMID: 21943684
16. Srx functions as a novel component to maintain the balance between H2O2 production and elimination PMID: 22086924
17. Srx-Prx IV axis is critical for lung cancer maintenance and metastasis, suggesting that targeting the Srx-Prx IV axis may provide unique effective strategies for cancer prevention and treatment. PMID: 21487000
18. sulfiredoxin 1 is associatd with the pathogenesis of human pulmonary fibrosis. PMID: 20718723
19. Studies present the 2.1 A crystal structure of human Srx in complex with PrxI, ATP, and Mg(2+). PMID: 19812042
20. The reduction of the cysteine sulfinic acid moiety within the active site of the peroxiredoxin by sulfiredoxin involves novel sulfur chemistry and the use of ATP and Mg(2+). PMID: 15952770
21. analysis of the reduction of cysteine sulfinic acid of peroxiredoxin to cysteine by mammalian sulfiredoxin PMID: 16565085
22. Actin and protein tyrosine phosphatase 1B were identified in vitro as targets of sulfiredoxin 1 (Srx1)-dependent deglutathionylation. PMID: 16818657
23. Aspartate-187 of peroxiredoxin (Prx) I is the catalytic residue responsible for ATP hydrolysis in the cysteinesulfinic acid reduction of Prx by human sulfiredoxin. PMID: 17176052
24. 2.6 A crystal structure of the human Srx-PrxI complex [Srx] PMID: 18172504
25. Reduction of cysteine sulfinic acid in peroxiredoxin by sulfiredoxin proceeds directly through a sulfinic phosphoryl ester intermediate PMID: 18579529
26. analysis of a protein thiosulfinate intermediate in the reduction of cysteine sulfinic acid in peroxiredoxin by human sulfiredoxin PMID: 18593714
27. decreased expression in lungs from patients with chronic obstructive pulmonary disorder PMID: 19027064
28. The current study identifies Sulfiredoxin as a unique target of activator protein-1 (AP-1) activation and TAM67 inhibition. PMID: 19057013
29. Deglutathionylation of 2-Cys Prx is specifically catalyzed by Srx. PMID: 19561357

Show More

Hide All

HGNC: 16132

OMIM: 617583

KEGG: hsa:140809

STRING: 9606.ENSP00000371388

UniGene: Hs.516830